Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RNA viruses as virotherapy agents.

Stephen J Russell1

  • 1Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA. sjr@mayo.edu

Cancer Gene Therapy
|January 11, 2003
PubMed
Summary

RNA viruses show promise for oncolytic virotherapy, targeting cancer by exploiting tumor-specific defects in cellular defenses. Engineering these viruses enhances their tumor specificity and therapeutic potential.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same author

Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition.

Molecular therapy. Oncology·2026
Same author

Low-density lipoproteins in human serum competitively inhibit the binding and entry of vesicular stomatitis virus.

Molecular therapy. Advances·2026
Same author

Cancer viroimmunotherapy platforms based on varicella-zoster virus and cytomegalovirus.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.

Cell reports. Medicine·2024
Same author

Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification.

Molecular therapy. Oncology·2024

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • RNA viruses are emerging as potent oncolytic virotherapy agents.
  • Double-stranded RNA formation activates cellular defenses (PKR, interferon).
  • Tumors often have defective PKR and interferon pathways, promoting viral replication.

Purpose of the Study:

  • To summarize the current status of oncolytic virotherapy using RNA viruses.
  • To highlight seven specific RNA viruses under investigation for cancer treatment.

Main Methods:

  • Review of current research on oncolytic RNA viruses.
  • Analysis of viral characteristics and tumor interactions.
  • Discussion of virus engineering for enhanced specificity.

Main Results:

  • Tumor cells are often permissive to RNA virus replication due to immune pathway defects.
  • Natural or adapted tumor specificity is observed in many oncolytic RNA viruses.
  • Virus engineering offers a route for optimizing oncolytic agents.

Conclusions:

  • Oncolytic RNA virotherapy is a rapidly developing field with significant therapeutic potential.
  • Seven distinct RNA viruses are being explored for their oncolytic capabilities.
  • Further refinement through genetic engineering is key to maximizing efficacy.

Related Experiment Videos